Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 20, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"). As a result of a fund movement on June 16, 2006, holdings increased from 17,454,333 to 17,504,816 shares. The average price for this movement was $54.59.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that Directors Dr. J.P. Garnier and Dr. M. Slaoui are potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- The transaction involved an increase of 50,483 Ordinary Share ADRs in the US Retirement Savings Plan.
- The transaction date was June 16, 2006, with notification provided on June 20, 2006.
- The average price per share for the movement was $54.59.
- Directors Dr. J.P. Garnier and Dr. M. Slaoui are identified as potentially interested parties in the fund.